Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 48
- Registration Number
- NCT00421226
- Locations
- 🇯🇵
Novartis Investigative site, Tokyo, Japan
Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00420836
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00420043
Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients
Phase 4
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 313
- Registration Number
- NCT00419926
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00419887
- Locations
- 🇨🇳
Novartis, Beijing, China
Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension
Phase 4
Completed
- Conditions
- Osteoarthritis With Controlled Hypertension
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 78
- Registration Number
- NCT00419796
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00419172
Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00418509
- Locations
- 🇬🇧
Novartis, Horsham, United Kingdom
Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 72
- Registration Number
- NCT00418002
- Locations
- 🇬🇧
Novartis Investigative Site, Horsham, United Kingdom
Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.
Phase 1
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 35
- Registration Number
- NCT00417820
- Locations
- 🇦🇹
Novartis Investigative Site, Vienna, Austria
© Copyright 2025. All Rights Reserved by MedPath